Special Issue

Advances in Targeted Therapy for Gastrointestinal Cancers

Message from the Guest Editors

This Special Issue, "Advances in Targeted Therapy for Gastrointestinal Cancers", aims to highlight recent progress and emerging strategies in the development of targeted therapies for gastrointestinal (GI) malignancies. GI cancers, including those of the esophagus, stomach. pancreas, liver, bile ducts, small intestines, colorectum. and anus, represent a significant global health burden. In recent years, we have witnessed the development of targeted therapies and immunotherapies, which dramatically improved the outcomes for many patients. However, many challenges remain, as only a small subset of GI cancer patients benefits from currently approved drugs. Furthermore, due to complex tumor biology, both primary and acquired resistance frequently occur. Along with new medications, there is also a need for better prognostic and predictive biomarkers. By gathering cutting-edge findings and expert perspectives, this Special Issue seeks to foster scientific exchange and accelerate the development of more effective, personalized treatments for patients with gastrointestinal cancers.

Guest Editors

Dr. Juraj Prejac

- 1. Department of Oncology, University Hospital Centre Zagreb, Kišpatićeva 12, 10000 Zagreb, Croatia
- 2. School of Dental Medicine, University of Zagreb, Gundulićeva 5, 10000 Zagreb, Croatia

Dr. Marin Golčić

- 1. Tumor Clinic, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia
- 2. School of Medicine, University of Rijeka, 51000 Rijeka, Croatia

Deadline for manuscript submissions

31 January 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/249227

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

